Dear Editor-in-Chief,

Recently, *Zhang* et al. published "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China" \[[@bb0005]\]. We have read with great interest this review. As mentioned, current knowledge of anti-inflammation treatment in COVID-19 patients supports the use of glucocorticoids, tocilizumab, JAK inhibitors, chloroquine and hydroxychloroquine \[[@bb0005]\].

The emergence of a new SARS-CoV-2 betacoronavirus has led to a major health-related crisis resulting in significant mortality in intensive care units (ICU), due to pulmonary complications of COVID-19 \[[@bb0005]\]. Mortality is also associated with advanced chronological age, diabetes, or cardiovascular disease \[[@bb0005]\].

Reduced counts and functional exhaustion of T lymphocytes, and cytokine release syndrome have been identified as adverse factors in patients affected by severe SARS-CoV-2 infection \[[@bb0010],[@bb0015]\]. Severe COVID-19 can therefore mimic a state of immune senescence \[[@bb0020]\].

In COVID-19, the serine/threonine kinase mTOR (mechanistic Target Of Rapamycin) pathways may offer valuable targets to control cell injury, oxidative stress, and the onset of hyperinflammation \[[@bb0025]\]. mTOR is a central regulator of inflammation within the immune system \[[@bb0030],[@bb0035]\] and a sensor of oxidative stress \[[@bb0040]\]. mTOR forms two complexes: mTORC1 mediates TH1 and TH17 differentiation at the time of viral antigenic presentation by dendritic cells (DC) \[[@bb0045]\]; mTORC2 mediates TH2 differentiation; while both complexes restrict regulatory T-cell (Treg) differentiation \[[@bb0035]\]. With regards to T cells, mTORC1 activation is consequence of oxidative stress, which can be blocked by *N*-acetylcysteine in Systemic Lupus Erythematosus (SLE) patients \[[@bb0050]\]. Consistent with its role in pro-inflammatory T-cell differentiation, mTORC1 activation is involved in SLE patients which can be blocked by rapamycin \[[@bb0035]\]. In addition, mTORC1 is thus known as the rapamycin-sensitive complex \[[@bb0045]\].

The aim of this letter is to discuss the potentiality for rapamycin (sirolimus), an mTOR inhibitor, to restore T-cell functionality and decrease cytokine storm.

Cytokine storm, a hyper-inflammatory reaction in which cytokines are produced rapidly and extensively by immune cells in reaction to endogenous or exogenous stress \[[@bb0055]\], is a major contributor to acute respiratory distress syndrome and multiple organ dysfunction syndrome \[[@bb0055]\].

In severe COVID-19 patients, IL-2, IL-6, IL-7, IL-10, TNF-α, G-CSF, IP-10, MCP-1, and MIP-1α levels increase significantly \[[@bb0005],[@bb0010]\]. Among these, several cytokines are involved in TH17 type responses. IL-1β and TNF-α (TH17 and TH1 cells highly express TNF-α), both promote TH17 responses and vascular permeability and leakage \[[@bb0060]\]. COVID-19 expands TH17 cells further supporting a TH17 type cytokine storm in this disease \[[@bb0060]\]. Cytokine storm may promote T-cell apoptosis, necrosis or pyroptosis, causing reduced T-cell counts \[[@bb0010]\].

T-cell senescence is a state of T-cell dysfunction that occurs in chronic infections and cancer \[[@bb0010],[@bb0020]\]. In COVID-19, patients over 60 years, and patients in ICU care have a decrease in CD4+, CD8+, and total T-cell numbers \[[@bb0010]\], and this is inversely correlated with patients\' survival \[[@bb0010]\].

T cells play a vital role in viral clearance, particularly through secretion of cytotoxicity molecules such as perforin, granzyme and IFN-γ \[[@bb0015]\]. However, patients with severe form of COVID-19 have less multifunctional and more non-functional CD4+ T cells, as well as higher senescent CD8+ T cells, that are unable to secrete the cytotoxicity molecules, than patients with mild COVID-19 \[[@bb0015]\]. Also, reduced T-cell numbers are negatively correlated with serum IL-6, IL-10 and TNF-α \[[@bb0010]\] with higher levels of senescence markers PD-1 and Tim-3 \[[@bb0010]\], CTLA-4 and TIGIT \[[@bb0015]\]. These constitute a hallmark of severe forms of COVID-19 \[[@bb0010],[@bb0015]\]. In addition, senescent cells are known to secrete a broad spectrum of molecules such as cytokines (IL-1β, IL-6, IL-8, IL-10, IL-17, TNF-α...), chemokines, proteases and growth factors, which distinguish them from healthy cells present within tissues \[[@bb0065]\]. These factors represent a typical hallmark of senescence and therefore they have been defined as senescence-associated secretory phenotype (SASP) \[[@bb0065]\]. Taken together, T-cell senescence might be the *primum movens* of cytokine storm in severe COVID-19 \[[@bb0070]\].

In these patients, the potential of rapamycin, a specific mTOR inhibitor that can promote autophagy and suppress the SASP, to reverse T-cell senescence can be discussed \[[@bb0075]\].

In elderly with increased senescent PD-1+ T-cells, everolimus (an analog of rapamycin) enhanced immune function, and improved T-cell responses to antigenic stimulation with an acceptable risk/benefit balance \[[@bb0020]\]. In elderly with coronary artery disease, rapamycin reduced serum senescence markers through IL-6 suppression \[[@bb0080]\].

In patients infected with the H1N1 influenza virus, early adjuvant rapamycin therapy during a short period (2 mg/day for 14 days) was significantly associated with an increased viral clearance, a greater improvement in lung injury (i.e. less hypoxemia), and a decrease of multiple organ dysfunction. The duration of ventilation in survivors was also shortened \[[@bb0085]\].

In a mouse model, H1N1 causes acute lung injury in an IL-17-dependent manner \[[@bb0090]\]. mTOR blockade with rapamycin might inhibit the expansion of Th17 cells in COVID-19 patients such as in Systemic Lupus Erythematosus patients \[[@bb0095],[@bb0100]\].

H1N1 and SARS-CoV-2 both activate mTOR, and NLRP3 inflammasome pathway \[[@bb0025],[@bb0105]\] leading to the production IL-1β, the mediator of lung inflammation, fever and fibrosis \[[@bb0025],[@bb0085]\] and induces pyroptosis, a hyperinflammatory form of cell death \[[@bb0110]\]. Rapamycin inhibits H1N1-induced mTOR pathway activation, and thus IL-1β secretion \[[@bb0105]\]. In COVID-19, the binding of SARS-CoV-2 to Toll Like Receptor (TLR), which leads to IL-1β production, could be reversed by rapamycin \[[@bb0115]\].

Furthermore, rapamycin promotes de novo expression of Foxp3 in naive T cells, leading to Treg proliferation and survival in vivo and in vitro \[[@bb0045]\]. As a result, rapamycin inhibits effector T-cell proliferation and promotes Treg accumulation \[[@bb0045]\].

In addition, rapamycin was recently identified in a network-based drug repurposing study as a candidate for potential use in COVID-19 \[[@bb0115]\].
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The adverse effects of rapamycin are well known and include leukopenia, thrombocytopenia, diarrhea, stomatitis, hypercholesterolemia, and rarely interstitial pneumonitis \[[@bb0120]\].

Associated to antiviral therapy, rapamycin could optimize the treatment of COVID-19 patients with advanced chronological age, and/or comorbidities, or those with reduced T-cell counts who are more likely to progress to severe disease.

To date, there is one registered clinical trial of rapamycin: "Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE)" (NCT04341675).
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